Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth Group, and Align Technology Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 19, 2013 NEW YORK, November 19, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Baxter International Inc. (NYSE: BAX), Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group Inc. (NYSE: UNH), and Align Technology, Inc. (NASDAQ: ALGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On November 14, 2013, Pfizer Inc. (Pfizer) announced that Wyeth LLC, the Company's wholly owned subsidiary, has notified The Bank of New York Mellon, as trustees under the applicable indenture, of its election to fully redeem all of its outstanding 5.5% Notes due February 1, 2014 (CUSIP No. 983024AE0) (the Notes). Pfizer informed that the aggregate principal amount of Notes currently outstanding is c.$1.8 billion, and the redemption date for the Notes will be December 16, 2013. Pfizer added that the redemption price for the notes will be a price equal to the greater of 100% of the principal amount of the Notes or the sum, as determined by the Quotation Agent (as defined in the Global Note, the form of which was filed with the Securities and Exchange Commission as part of Exhibit 4.6 to Wyeth's Annual Report on Form 10-K for the fiscal year ended December 31, 2003 (File No. 001-01225), of the present value of the principal amount of the Notes and the remaining scheduled payments of interest on the Notes from the Redemption Date to the maturity date of the Notes, exclusive of interest accrued to the Redemption Date, discounted from their respective scheduled payment dates to the Redemption Date on a semiannual basis (assuming a 360-day year of twelve 30-day months) at the Treasury Rate (as defined in the Global Note) plus 25 basis points, plus accrued and unpaid interest on the principal amount being redeemed to (but excluding) the Redemption Date. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d702_PFE -- Baxter International Inc. Research Report On November 14, 2013, Baxter International Inc. (Baxter) announced that the Company will present at the 25^th Annual Piper Jaffray Healthcare Conference on December 3, 2013, at 12:00 p.m. CT. Baxter added that a live webcast of its presentation will be accessible through its corporate website and will be available for replay until January 2, 2014. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/163d_BAX -- Eli Lilly & Co. Research Report On November 14, 2013, Eli Lilly & Co. (Lilly) announced that the Company will invest more than $700 million to enhance its global insulin manufacturing capacity. According to Lilly, the new manufacturing investments will support both existing and future insulin-based medicines which will be distributed as follows: $120 million to enhance insulin cartridge manufacturing capacity in France, $245 million to expand insulin-active-ingredient and delivery device manufacturing capacity in Indianapolis and Puerto Rico, and $350 million to expand insulin cartridge manufacturing capacity in China. The Company informed that its commitment to expand insulin production in China is the latest in a series of diabetes-related investments in the region, such as the opening of the Lilly China Research and Development Center at Shanghai in 2012. Lilly added that it has now raised its manufacturing commitment in 2013 to more than $1 billion in planned investments in response to the growing diabetes epidemic and increasing demand for insulin around the world. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/977d_LLY -- UnitedHealth Group Inc. Research Report On November 12, 2013, UnitedHealth Group Inc. (UnitedHealth Group) announced that the Company's NOT ME online platform was named a CES Innovations 2014 Design and Engineering Award honoree. The Company said that the NOT ME online platform delivers the Diabetes Prevention Program (DPP) via the Internet to people at their own convenience. Deneen Vojta, Senior Vice President, UnitedHealth Center for Health Reform and Modernization, said, "Through the online NOT ME program, consumers learn strategies that can help them lose weight and improve their health - and they can participate at home or anywhere they chose that is convenient and fits their busy lifestyles. We are grateful to be recognized by the CES Innovations Design and Engineering Awards for our commitment to helping people live healthier lives." The Company's online NOT ME program will be displayed at the 2014 International CES on January 7, 2014 to January 10, 2014 at The Venetian in Las Vegas. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/73e5_UNH -- Align Technology, Inc. Research Report On November 14, 2013, Align Technology, Inc.'s (Align Technology) stock declined 6.34%, ending the day at $54.68. Over the previous three trading sessions, shares of Align Technology declined 6.67% compared to the Nasdaq Composite which gained 1.35% during the same period. The Full Research Report on Align Technology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/69b3_ALGN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth
Press spacebar to pause and continue. Press esc to stop.